Fennec Pharmaceuticals Inc. Common Stock (FENC) is a publicly traded Healthcare sector company. As of May 21, 2026, FENC trades at $9.69 with a market cap of $333.48M and a P/E ratio of -28.41. FENC moved +0.00% today. Year to date, FENC is +30.00%; over the trailing twelve months it is +19.34%. Its 52-week range spans $3.96 to $10.27. Analyst consensus is strong buy with an average price target of $14.67. Rallies surfaces FENC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Fennec to Present Four PEDMARK Otoprotection Studies at ASCO 2026: Four abstracts accepted at ASCO 2026 explore PEDMARK’s efficacy in preventing cisplatin-induced hearing loss: pediatric STS-J01, metastatic GCT Phase 1, young adult tolerability, and head-and-neck audiometric outcomes. PEDMARK is FDA-approved for pediatric use, holds a NCCN 2A adolescent recommendation, and targets ototoxicity affecting 60–90% of cisplatin patients.
| Metric | Value |
|---|---|
| Price | $9.69 |
| Market Cap | $333.48M |
| P/E Ratio | -28.41 |
| EPS | $-0.34 |
| Dividend Yield | 0.00% |
| 52-Week High | $10.27 |
| 52-Week Low | $3.96 |
| Volume | 5.24K |
| Avg Volume | 0 |
| Revenue (TTM) | $44.64M |
| Net Income | $-9.74M |
| Gross Margin | 0.00% |
4 analysts cover FENC: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $14.67.